IRIDEX (NASDAQ:IRIX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of IRIDEX (NASDAQ:IRIX) in a research report released on Sunday morning. The brokerage issued a hold rating on the medical equipment provider’s stock.

IRIDEX Stock Down 4.5 %

Shares of IRIDEX stock opened at $1.69 on Friday. The company has a quick ratio of 0.86, a current ratio of 1.54 and a debt-to-equity ratio of 0.55. IRIDEX has a 12-month low of $1.27 and a 12-month high of $3.65. The firm has a market capitalization of $28.11 million, a PE ratio of -2.52 and a beta of 0.80. The stock’s fifty day moving average is $1.67 and its 200-day moving average is $2.01.

IRIDEX (NASDAQ:IRIX) last posted its quarterly earnings data on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share (EPS) for the quarter. The company had revenue of $11.58 million for the quarter. IRIDEX had a negative return on equity of 192.95% and a negative net margin of 22.79%. During the same quarter in the previous year, the firm posted ($0.11) EPS.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.